Presentation Information
[P-R3-20]Analytical Strategy for Evaluating High-Specific-Activity 177Lu in Theranostic Radiopharmaceutical Production
*Miki Harigai1, Kazumi Nakano2, Kenji Shirasaki3, Hiroyuki Kimura4, Tomoo Yamamura1 (1. Institute for Integrated Radiation and Nuclear Science, Kyoto University (Japan), 2. Agilent Technologies, Inc. (Japan), 3. Institute for Radiation Science, The University of Osaka (Japan), 4. Institute for Environmental Safety and Health, Kyoto University (Japan))
Keywords:
ICP-MS,Lu-177,Theranostic Radiopharmaceutical,Actinides